Apyx Medical Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AM</div>
APYX -- USA Stock  

USD 4.98  0.11  2.16%

In general, we focus on analyzing Apyx Medical (NASDAQ:APYX) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apyx Medical daily price indicators and compare them against related drivers. While this unique economic environment continues, Apyx Medical may throw investors more surprises in two-three weeks. We will evaluate if Apyx Medical shares are reasonably priced going into September.
Published over a month ago
View all stories for Apyx Medical | View All Stories
Should I exit my Apyx Medical (NASDAQ:APYX) holdings?
This firm's average rating is Buy from 3 analysts. We provide trade advice to complement the prevailing expert consensus on Apyx Medical. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. The company has Profit Margin (PM) of (58.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (81.99) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.82.
The successful prediction of Apyx Medical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Apyx Medical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Apyx Medical based on Apyx Medical hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Apyx Medical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Apyx Medical's related companies.

Use Technical Analysis to project Apyx Medical expected Price

Apyx Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Apyx Medical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Apyx Medical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Apyx Medical utilizes its cash?

To perform a cash flow analysis of Apyx Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Apyx Medical is receiving and how much cash it distributes out in a given period. The Apyx Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Apyx Medical Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Apyx Medical reported Net Cash Flow from Operations of (18.48 Million) in 2019

Acquisition by Minnie BaylorHenry of 17000 shares of Apyx Medical subject to Rule 16b-3

Legal trades by Apyx Medical insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Apyx Medical insider trading alert for grant of stock option (option to buy) by Minnie BaylorHenry, the corporate stakeholder, on 10th of August 2020. This event was filed by Apyx Medical Corp with SEC on 2020-08-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Apyx Medical Indicators

The company reported the previous year's revenue of 27.6 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 19.09 M.
 2017 2018 2019 2020 (projected)
Current Assets22.55 M89.83 M76.73 M82.79 M
Total Assets30.99 M95.93 M84.75 M68.18 M

Cost of Revenue Breakdown

Apyx Medical Cost of Revenue yearly trend continues to be fairly stable with very little volatility. Cost of Revenue is likely to outpace its year average in 2020. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Apyx Medical Cost of Revenue is fairly stable at the moment as compared to the past year. Apyx Medical reported Cost of Revenue of 9.14 Million in 2019
201314.46 Million
201418.69 Million
201516.96 Million
20163.7 Million
20173.28 Million
20185.78 Million
20199.14 Million
20209.88 Million

Apyx Medical showing appearance of lower volatility

Risk adjusted performance is down to 0.19. It may suggest a possible volatility slide. Apyx Medical is displaying above-average volatility over the selected time horizon. Investors should scrutinize Apyx Medical independently to ensure intended market timing strategies are aligned with expectations about Apyx Medical volatility.

Our Conclusion on Apyx Medical

While other entities within the medical devices industry are still a little expensive, even after the recent corrections, Apyx Medical may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Apyx Medical valuation and our trade advice on Apyx Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apyx Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Apyx Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com